معرفی
Zhenjia Wang is an Associate Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo’s School of Pharmacy and Pharmaceutical Sciences. Previously, he held positions at Washington State University (2014–2024) and the University of Illinois at Chicago (2007–2014). His research focuses on developing novel drug delivery systems using nanoparticles, neutrophils, and bacterial membrane-derived nanovesicles to treat cancers, inflammatory diseases, and infections. Key achievements include discovering neutrophils as transporters for crossing blood-brain barriers and creating nanoparticle formulations to target tumor microenvironments.
Education: PhD in Condensed Matter Physics from the Chinese Academy of Sciences (1995), BS in Optics from Liaoning University, China (1989).
Research interests span biomedical imaging, drug delivery across vascular barriers, and nanotechnology applications. He leads NIH-funded projects, including a $1.37M grant for nanovesicle drug loading and a $1.69M grant on neutrophil-mediated delivery. Awards include the NIH Career Development Award (2012) and American Heart Association Scientist Award (2011).
Service roles include NIH study sections (DBTD, SBIR, Nanotechnology) and editorial positions at Frontiers in Immunology and Pharmaceutics. His work bridges molecular biology, immunology, and bioengineering to advance targeted therapies.
